HER2-mutant microfluidics-embedded PXDOT models were used to study therapeutic responses to gefitinib, afatinib and neratinib (all at 0.5 μM) over 96 h using dual immunofluorescent staining to identify live/dead tumour cells. Here, ERBB2 is linked to neoplasm.